Health Catalyst (NASDAQ:HCAT) Price Target Raised to $13.00 at JPMorgan Chase & Co.

Health Catalyst (NASDAQ:HCAT) had its price objective boosted by JPMorgan Chase & Co. from $10.00 to $13.00 in a research report report published on Wednesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other research firms also recently issued reports on HCAT. Stephens dropped their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an equal weight rating on the stock in a research note on Thursday, August 8th. Piper Sandler reduced their price target on Health Catalyst from $14.00 to $11.00 and set an overweight rating for the company in a research report on Monday, August 26th. Cantor Fitzgerald reiterated an overweight rating and issued a $16.00 target price on shares of Health Catalyst in a research note on Tuesday, August 20th. Canaccord Genuity Group reiterated a buy rating and issued a $11.00 target price on shares of Health Catalyst in a report on Tuesday, May 21st. Finally, Wells Fargo & Company lowered their price target on shares of Health Catalyst from $14.00 to $13.00 and set an overweight rating on the stock in a report on Friday, May 10th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus target price of $11.42.

Health Catalyst Trading Up 4.0 %

NASDAQ HCAT opened at $7.54 on Wednesday. The stock has a market cap of $445.12 million, a PE ratio of -4.08 and a beta of 1.31. The company’s 50-day moving average price is $6.82 and its 200-day moving average price is $6.94. Health Catalyst has a 12 month low of $5.42 and a 12 month high of $11.98.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. The firm had revenue of $75.90 million during the quarter, compared to analyst estimates of $74.96 million. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. Health Catalyst’s quarterly revenue was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.21) earnings per share. As a group, sell-side analysts forecast that Health Catalyst will post -0.37 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Monday, August 5th. The shares were sold at an average price of $6.19, for a total transaction of $32,243.71. Following the completion of the sale, the chief operating officer now directly owns 150,006 shares in the company, valued at $928,537.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders have sold 13,035 shares of company stock valued at $81,396. Insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Health Catalyst by 23.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,072 shares of the company’s stock worth $140,000 after buying an additional 2,817 shares during the period. New York State Common Retirement Fund raised its holdings in shares of Health Catalyst by 1.3% during the fourth quarter. New York State Common Retirement Fund now owns 122,967 shares of the company’s stock worth $1,139,000 after purchasing an additional 1,582 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Health Catalyst during the fourth quarter worth $108,000. Charles Schwab Investment Management Inc. lifted its position in Health Catalyst by 19.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 521,362 shares of the company’s stock valued at $4,828,000 after purchasing an additional 85,777 shares during the period. Finally, Versor Investments LP grew its position in Health Catalyst by 150.0% during the 4th quarter. Versor Investments LP now owns 29,000 shares of the company’s stock worth $269,000 after purchasing an additional 17,400 shares during the period. 85.00% of the stock is owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.